McWeenie rears his horned head again
Kathleen
[Add to Address Book]
To:
criminal...@usdoj.gov,alberto....@usdoj.gov,Spin...@yahoogroups.com,ne...@nature.com,edw...@mcsweegan.com,EM...@NIH.GOV,ctl...@yahoogroups.com,atorney...@po.state.ct.us,let...@washpost.com,let...@courant.com,patrick....@jud.state.ct.us,
"Steve Erickson" <tr...@hotmail.com>, attorney...@po.state.ct.us,
pm...@cdc.gov, Spin...@yahoogroups.com, ctl...@yahoogroups.com,
james....@po.state.ct.us, robin_...@reid.senate.gov,
eliot....@oag.state.ny.us, JGerb...@cdc.gov, go...@cdc.gov,
CTL...@yahoogroups.com, camp...@courant.com, jhorn...@fff.org,
edi...@commondreams.org, hor...@courant.com, cohen...@aol.com,
leonar...@po.state.ct.us, mcne...@aol.com, o...@po.state.ct.us,
thoma...@po.state.ct.us, fr...@courant.com, cpoi...@courant.com,
will...@senatedems.ct.gov, kenneth...@po.state.ct.us,
inst...@thenation.com, han...@senatedems.ct.gov,
ltgoverno...@po.state.ct.us, ubi...@courant.com,
fra...@ucia.gov, govern...@po.state.ct.us, con...@po.sta
Cc: feed...@canada.com, l...@cnn.com,mark....@yale.edu,
criminal...@usdoj.gov, patrick.f...@usdoj.gov,
karla.d...@usdoj.gov, thomas...@usodj.gov, mac...@yahoo.com,
cust...@nlm.nih.gov, rti...@mdlab.com, rcti...@comcast.net,
ltsh...@aol.com, vts...@aol.com, FalN...@aol.com
Subject: NIH's Edward McSweegan on a cime he participated in. CDC
staff with their names on SmithKline patents
Date: Thursday, March 16, 2006 13:47:12 [View Source]
(Below)
Note that Ed was an approver of the bogus CDC method to diagnose Lyme,
so that
most of the adverse events and vaccine failures would not be recorded
http://actionlyme.org/Dearborn_Who_Approved.htm
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf
Here's what typically happpened to the vaccine injurees:
http://actionlyme.org/Bull_Lewis.htm
They were laughed out the door and told, "Ha, Ha, aren't we *all*
getting old?!"
And of course, McSweegan stalks and harassed Lyme victims and many,
many others.
He's made a career out of it.
http://actionlyme.org/McSweegan.htm
http://actionlyme.org/GOLDWATER_LETTER.htm
Go ahead and read what he wrote to Senator Barry Goldwater. This guy
is another
psychopath with a dot guv paycheck.
KMDickson
http://actionlyme.org
>
>
>
> http://www.nature.com/nature/journal/v440/n7082/full/440278b.html
> Correspondence
>
> Nature 440, 278 (16 March 2006) | doi:10.1038/440278b
> Lyme vaccine demonized by advocacy groups
>
> Edward McSweegan1
>
> 1. 1692 Barrister Court, Crofton, Maryland 21114, USA
>
> Sir:
>
> As a microbiologist who managed a federal programme on Lyme disease in the
1990s, I consider that any new clinical trials of a vaccine candidate
based on
the protein OspA, as mentioned in your News Feature "Uphill struggle"
(Nature
439, 524-525; 2006), should be confined to Europe, for three reasons.
>
> First, Lyme disease is non-communicable, readily treatable with common
antibiotics and geographically localized in the United States.
Neurological
cases - where treatment can be problematic - are more common in
Europe and a new
vaccine may reduce the costs and consequences of infection.
>
> Second, European experience with the widely used tick-borne encephalitis virus
(TBEV) vaccine may facilitate vaccine-trial recruitment and greater
public
acceptance of a new Lyme vaccine.
>
> Third, Europe is a less litigious environment and is largely free of organized
Lyme-patient advocacy groups. In the United States, activists have
turned Lyme
disease into everyone's backyard bogeyman. They have demonized experts
for their
views on treatment and prevention, and hired lawyers to successfully
argue the
dangers of vaccine-induced autoimmunity (Philadelphia Inquirer B03,
July 9
2003).
>
> The activists are already using Internet discussion groups to warn against a
new vaccine. One of them recently wrote "I would encourage all Lyme
patients to
consider writing letters, emphasizing the lack of demand for the last
vaccine,
and also the fact that any future vaccines can expect a lack of
cooperation,
protests, legal quagmires, etc."
>
> A careful, hysteria-free trial of the new OspA vaccine in Europe may help to
undermine the opposition to it in the United States.
>
http://info.nature.com/cgi-bin24/DM/y/eXL70B4UuZ0Ch0wrf0EQ
Correspondence
Nature 440, 278 (16 March 2006) | doi:10.1038/440278c
Lyme vaccine: studies have raised genuine concerns
Carl Brenner1
1. Lamont-Doherty Earth Observatory of Columbia University, Route
9W,
Palisades, New York 10964, USA
Sir:
The lamentable hostilities between researchers into Lyme disease and
the
patients on whose behalf they purportedly labour will not be eased by
Nature's
account of the issues surrounding GlaxoSmithKline's decision to pull
its
vaccine, LYMErix, from the market ("Uphill struggle" Nature 439,
524-525; 2006).
The News Feature portrays truth-seeking researchers on one side and
angry
patients and their advocates on the other, with the latter torpedoing a
perfectly good vaccine with scare tactics and bad publicity. But a
significant
portion of the Lyme research community had strong reservations about
the
product. LYMErix's initial approval by the vaccine advisory committee
of the US
Food and Drug Administration (FDA) was hedged with caveats that
questioned its
safety and even its usefulness (J. Am. Med. Assoc. 279, 1937-1938;
1998). One
case series in the peer-reviewed medical literature describes a group
of six
patients, with no history of neurologic problems, who developed
neuropathy or
cognitive impairment shortly after receiving the vaccine (J. Peripher.
Nerv.
Syst. 9, 165-167; 2004).
And there were other factors that hindered its success in the
marketplace. It
was relatively expensive at $50 per inoculation, and it required three
doses,
spaced over a period of one year, to achieve its full efficacy rate,
which
topped out at only 79%. Perhaps most disappointingly, study subjects
lost their
immunity relatively quickly, meaning that booster shots would be
required every
year or two - shots that the FDA's advisory committee refused to
sanction
without further study
(http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.pdf). In
addition, the
vaccine was not approved for children under the age of 15.
--
If you have an important point to make, don't try to be subtle or
clever. Use a
pile driver. Hit the point once. Then come back and hit it again. Then
hit it a
third time-a tremendous whack.
Winston Churchill
http://actionlyme.org
-------------- Original message ----------------------
From: kmdi...@comcast.net
> http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=AU4392093&F=8
>
> Compositions useful in diagnosis and prophylaxis of lyme disease
>
> Bibliographic data Description
> Claims Mosaics Original
document
> INPADOC legal status
>
>
>
> Patent number: AU4392093
> Publication date: 1993-12-30
>
> Inventor: GOLDE WILLIAM T; ROEHRIG JOHN T; BURKOT THOMNAS; PIESMAN JOSEPH
> F; JOHNSON BARBARA J B; MAYER LEONARD W; KEEN MARK G; HUNT ANN R *** [CDC
> staff] ***
>
> Applicant: SMITHKLINE BEECHAM CORP; US HEALTH
>
> Classification:
> - international: A61K39/02; C07K14/20; C07K16/12; A61K38/00; A61K39/02;
> C07K14/195; C07K16/12; A61K38/00; (IPC1-7): A61K39/00; A61K39/02; C07K3/00;
> C12Q1/00
> - european: A61K39/02D; C07K14/20; C07K16/12A10
> Application number: AU19930043920D 19930526
> Priority number(s): US19920889015 19920526; US19920944464 19920914;
> US19920992896 19921218
>
> View INPADOC patent family
>
> DESCRIPTION:
> http://v3.espacenet.com/textdes?DB=EPODOC&IDX=AU4392093&F=8&QPN=AU4392093
>
> "Summarv of the Invention
> In one aspect, the invention provides isolated
> B. burgdorferi antigens which are regulated and differentiated by growth of
the
> B. burgdorferi in a tick vector. Novel antigens of the invention are listed
> below in Table I.
>
> Certain of these antigens are characterized as being B. burgdorferi B31 strain
> specific and *** major histocompatibility complex(MHC) nonrestricted. Certain
> other of these antigens are characterized as being MHCrestricted. Sera
generated
> to these antigens (B31 MHC nonrestricted and B31 MHC restricted) are further
> characterized by the ability or lack of ability to react with B. burgdorferi
> JD-1 strain; the antigens themselves (B31 MHC nonrestricted and B31 MHC
> restricted) are further characterized by being homologous or heterologous with
> B. burgdorferi JD-1 strain antigens. The most preferred antigens of this
> invention, because of their ability to induce cross-strain immunity to B.
> burgdorferi in different animal haplotypes, are characterized by being B31 MHC
> nonrestricted, JD-1 crossreactive, and JD-1 nonrestricted.Other antigens are
> also useful in vaccine compositions and as diagnostics.***"
>
> - - - - -
>
> That means ***CDC knows*** that there is a genetic suscreptability to have the
> non-arthritis presentation of Lyme, just as there is a genetic susceptibility
to
> having arthritis Lyme.
>
> Strain B31 does not express much OspC, so CDC allowed the major "primary
> immunodpminant antigens," OspA, B, and C to be left out of the bloodwork for
> Lyme if anyone uses a lab which uses the B31 strain.
>
> Which is QUEST LABS and SmithKline.
>
> That means you lose the best 3 shots of having been indentified as having Lyme
> disease.
>
>
> Now you see that the CDC is complicit in this crime, because they clearly know
> better, and there is a *clear financial interest* for CDC staff to be spinning
> Lyme. If anyone uses these patented antigens in a recombinant form for either
a
> test or vaccine, they have to pay CDC staff royalties.
>
>
> KMDickson
> --
> If you have an important point to make, don't try to be subtle or clever. Use
a
> pile driver. Hit the point once. Then come back and hit it again. Then hit it
a
> third time-a tremendous whack.
> Winston Churchill
> http://actionlyme.org
>
>
>
> Yahoo! Groups Links
>
> <*> To visit your group on the web, go to:
> http://groups.yahoo.com/group/SpinLyme/
>
> <*> To unsubscribe from this group, send an email to:
> SpinLyme-u...@yahoogroups.com
>
> <*> Your use of Yahoo! Groups is subject to:
> http://docs.yahoo.com/info/terms/
>
>
>
SentMail: Email 1 of 267 Next »
Comcast © 2006 Comcast Cable Communications, Inc. All rights
reserved.